$EIGR "Searching for target‑specific and multi‑targeting organics for Covid‑19 in the Drugbank database with a double scoring approach". This recent one published in Scientific Reports (an open access Nature publication) is highly intriguing. It is a study that uses a computational approach to sift through the Drugbank database to screen compounds against the most important viral targets. The database holds information about 13,791 drugs. Now what: they identified few compounds that are able to bind to THREE important targets simultaneously and can serve as multi-targeting drugs. No, interferon lambda does not pop up. But shockingly LONAFARNIB does! A total of 8 compounds were identified binding to three targets, with only Baloxavir marboxil currently under investigation for COVID. It is an influenza antiviral approved in 2018 under the name XOFLUZA by Genentech / $RHHBY. Time to include Lonafarnib for COVID-19? uin$RHHBYG Reference: nature.com/articles/s41598-....
  • 2
2 Likes